Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Gamco Investors INC. ET AL

Gamco Investors INC. ET AL trimmed its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.5% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 239,843 shares of the medical equipment provider’s stock after selling 6,112 shares during the period. Gamco Investors INC. ET AL owned approximately 0.12% of Zimmer Biomet worth $23,625,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Dodge & Cox grew its stake in shares of Zimmer Biomet by 12.9% in the second quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock valued at $2,015,510,000 after buying an additional 2,533,009 shares in the last quarter. Norges Bank acquired a new position in Zimmer Biomet during the 2nd quarter worth about $225,867,000. AQR Capital Management LLC boosted its holdings in Zimmer Biomet by 276.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,300,593 shares of the medical equipment provider’s stock valued at $118,627,000 after acquiring an additional 955,284 shares during the period. Franklin Resources Inc. grew its position in Zimmer Biomet by 15.2% in the 2nd quarter. Franklin Resources Inc. now owns 4,673,860 shares of the medical equipment provider’s stock valued at $426,303,000 after acquiring an additional 615,014 shares in the last quarter. Finally, Invesco Ltd. grew its position in Zimmer Biomet by 11.5% in the 2nd quarter. Invesco Ltd. now owns 4,606,591 shares of the medical equipment provider’s stock valued at $420,167,000 after acquiring an additional 475,921 shares in the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ZBH. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday, February 10th. Canaccord Genuity Group dropped their price objective on shares of Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a report on Monday, November 10th. Evercore raised shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and upped their target price for the stock from $94.00 to $120.00 in a research note on Monday, January 5th. Robert W. Baird reiterated a “neutral” rating and set a $100.00 target price (down from $117.00) on shares of Zimmer Biomet in a report on Tuesday, December 16th. Finally, Wells Fargo & Company boosted their price target on shares of Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 11th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $106.20.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $94.08 on Friday. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55. The company has a fifty day simple moving average of $92.13 and a 200-day simple moving average of $95.73. The stock has a market cap of $18.41 billion, a P/E ratio of 26.58, a price-to-earnings-growth ratio of 1.91 and a beta of 0.58. Zimmer Biomet Holdings, Inc. has a 12-month low of $84.59 and a 12-month high of $114.44.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, beating the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The firm had revenue of $2.24 billion for the quarter, compared to analyst estimates of $2.22 billion. During the same quarter in the prior year, the company posted $2.31 earnings per share. Zimmer Biomet’s revenue for the quarter was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be issued a $0.24 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio is presently 27.12%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.